Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

 Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

Immunai Acquire Dropprint Genomics to Expand its Target Discovery Capabilities

Shots:

  • Immunai acquires the Dropprint Genomics and also expand its team with the hiring of new experts in immunology, single-cell technologies and machine learning
  • The acquisition and the new hiring will advance the Immunai’s work in single cell functional genomics to support discovery, prioritization, and development of new therapies and drug combinations
  • The acquisition happened a month after Immunai raised $60M in a Series A financing round and has raised $80M in funding to date

Click here ­to­ read full press release/ article | Ref: Web Wire | Image: 10x Genomics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post